Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Comment on the article "physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions".

Neuhoff S, Tucker GT.

Pharm Res. 2013 Jun;30(6):1467-8. doi: 10.1007/s11095-013-0988-5. Epub 2013 Mar 16. No abstract available.

PMID:
23504339
2.

Response to the comment on the article "physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions".

Varma MV, Lai Y, Feng B, Litchfield J, Goosen TC, Bergman A.

Pharm Res. 2013 Jun;30(6):1469-70. doi: 10.1007/s11095-013-0987-6. Epub 2013 Mar 6. No abstract available.

PMID:
23462935
3.

Physiologically based modeling of pravastatin transporter-mediated hepatobiliary disposition and drug-drug interactions.

Varma MV, Lai Y, Feng B, Litchfield J, Goosen TC, Bergman A.

Pharm Res. 2012 Oct;29(10):2860-73. doi: 10.1007/s11095-012-0792-7. Epub 2012 May 26.

PMID:
22638872
4.

Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans.

Watanabe T, Kusuhara H, Maeda K, Shitara Y, Sugiyama Y.

J Pharmacol Exp Ther. 2009 Feb;328(2):652-62. doi: 10.1124/jpet.108.146647. Epub 2008 Nov 10. Erratum in: J Pharmacol Exp Ther. 2011 May;337(2):568-9.

5.

The role of hepatic transport and metabolism in the interactions between pravastatin or repaglinide and two rOatp inhibitors in rats.

Badolo L, Bundgaard C, Garmer M, Jensen B.

Eur J Pharm Sci. 2013 Jul 16;49(4):767-72. doi: 10.1016/j.ejps.2013.04.030. Epub 2013 May 3.

PMID:
23648783
6.

Human liver-specific organic anion transporter, LST-1, mediates uptake of pravastatin by human hepatocytes.

Nakai D, Nakagomi R, Furuta Y, Tokui T, Abe T, Ikeda T, Nishimura K.

J Pharmacol Exp Ther. 2001 Jun;297(3):861-7.

7.

[Effect of pravastatin on transportation of scutellarin in mouse liver and its mechanism].

Liu JM, Xiong YQ.

Yao Xue Xue Bao. 2011 Mar;46(3):269-73. Chinese.

PMID:
21626779
8.

Culture period-dependent changes in the uptake of transporter substrates in sandwich-cultured rat and human hepatocytes.

Kotani N, Maeda K, Watanabe T, Hiramatsu M, Gong LK, Bi YA, Takezawa T, Kusuhara H, Sugiyama Y.

Drug Metab Dispos. 2011 Sep;39(9):1503-10. doi: 10.1124/dmd.111.038968. Epub 2011 Jun 14.

9.

Differential effects of pravastatin on the pharmacokinetics of paroxetine in normal and diabetic rats.

Li F, Ling ZL, Wang ZJ, Zhong ZY, Shu N, Zhang M, Liu C, Liu L, Liu XD.

Xenobiotica. 2017 Jan;47(1):20-30. doi: 10.3109/00498254.2016.1154999. Epub 2016 May 5.

PMID:
27145862
10.

Co-administration of paroxetine increased the systemic exposure of pravastatin in diabetic rats due to the decrease in liver distribution.

Li F, Xu D, Shu N, Zhong Z, Zhang M, Liu C, Ling Z, Liu L, Liu X.

Xenobiotica. 2015;45(9):794-802. doi: 10.3109/00498254.2015.1019592. Epub 2015 Jun 12.

PMID:
25915109
11.

Predicting individual responses to pravastatin using a physiologically based kinetic model for plasma cholesterol concentrations.

van de Pas NC, Rullmann JA, Woutersen RA, van Ommen B, Rietjens IM, de Graaf AA.

J Pharmacokinet Pharmacodyn. 2014 Aug;41(4):351-62. doi: 10.1007/s10928-014-9369-x. Epub 2014 Aug 9.

PMID:
25106950
12.

Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond.

Barton HA, Lai Y, Goosen TC, Jones HM, El-Kattan AF, Gosset JR, Lin J, Varma MV.

Expert Opin Drug Metab Toxicol. 2013 Apr;9(4):459-72. doi: 10.1517/17425255.2013.759210. Epub 2013 Jan 21. Review.

PMID:
23331046
13.

Evaluation of the uptake of pravastatin by perfused rat liver and primary cultured rat hepatocytes.

Ishigami M, Tokui T, Komai T, Tsukahara K, Yamazaki M, Sugiyama Y.

Pharm Res. 1995 Nov;12(11):1741-5.

PMID:
8592680
14.

Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1.

Bachmakov I, Glaeser H, Fromm MF, K├Ânig J.

Diabetes. 2008 Jun;57(6):1463-9. doi: 10.2337/db07-1515. Epub 2008 Feb 26.

15.

Pharmacokinetic modeling of the hepatobiliary transport mediated by cooperation of uptake and efflux transporters.

Kusuhara H, Sugiyama Y.

Drug Metab Rev. 2010 Aug;42(3):539-50. doi: 10.3109/03602530903491824. Review.

PMID:
20175646
17.

Tissue-selective uptake of pravastatin in rats: contribution of a specific carrier-mediated uptake system.

Yamazaki M, Tokui T, Ishigami M, Sugiyama Y.

Biopharm Drug Dispos. 1996 Dec;17(9):775-89.

PMID:
8968530
18.

Disposition and metabolism of pravastatin sodium in rats, dogs and monkeys.

Komai T, Kawai K, Tokui T, Tokui Y, Kuroiwa C, Shigehara E, Tanaka M.

Eur J Drug Metab Pharmacokinet. 1992 Apr-Jun;17(2):103-13.

PMID:
1425808
19.

Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants.

Ho RH, Choi L, Lee W, Mayo G, Schwarz UI, Tirona RG, Bailey DG, Stein CM, Kim RB.

Pharmacogenet Genomics. 2007 Aug;17(8):647-56.

20.

Synergistic interaction between genetics and disease on pravastatin disposition.

Clarke JD, Hardwick RN, Lake AD, Lickteig AJ, Goedken MJ, Klaassen CD, Cherrington NJ.

J Hepatol. 2014 Jul;61(1):139-47. doi: 10.1016/j.jhep.2014.02.021. Epub 2014 Mar 5.

Supplemental Content

Support Center